Ionis Pharmaceuticals (MEX:IONS) Cash from Discontinued Operating Activities : MXN0 Mil (TTM As of Mar. 2025)

View and export this data going back to 2019. Start your Free Trial

What is Ionis Pharmaceuticals Cash from Discontinued Operating Activities?

Cash from Discontinued Operating Activities is net cash from all of the entity's discontinued operating activities.

Ionis Pharmaceuticals's Cash from Discontinued Operating Activities for the three months ended in Mar. 2025 was MXN0 Mil. It means Ionis Pharmaceuticals received MXN0 Mil from discontinued investing activities. Ionis Pharmaceuticals's Cash from Discontinued Operating Activities for the trailing twelve months (TTM) ended in Mar. 2025 was MXN0 Mil.

Ionis Pharmaceuticals Cash from Discontinued Operating Activities Historical Data

The historical data trend for Ionis Pharmaceuticals's Cash from Discontinued Operating Activities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ionis Pharmaceuticals Cash from Discontinued Operating Activities Chart

Ionis Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash from Discontinued Operating Activities

Get a 7-Day Free Trial

Ionis Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Cash from Discontinued Operating Activities	Get a 7-Day Free Trial															-	-	-	-	-

Ionis Pharmaceuticals Cash from Discontinued Operating Activities Calculation

Cash from Discontinued Operating Activities is net cash from all of the entity's discontinued operating activities.

Cash from Discontinued Operating Activities for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN0 Mil.

Ionis Pharmaceuticals Cash from Discontinued Operating Activities Related Terms

Thank you for viewing the detailed overview of Ionis Pharmaceuticals's Cash from Discontinued Operating Activities provided by GuruFocus.com. Please click on the following links to see related term pages.

Ionis Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ionis Pharmaceuticals Inc (MEX:IONS) » Definitions » Cash from Discontinued Operating Activities

Comparable Companies

Traded in Other Exchanges

IONS:USA 0JDI:UK ISI:Germany

Address

2855 Gazelle Court, Carlsbad, CA, USA, 92010

Website

https://www.ionis.com

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.